Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab Single Dose in Japanese Patients with Knee Osteoarthritis
NCT00669409Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2008
- Primary completion
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tanezumab in osteoarthritis (OA) (6 arms), sponsored by Pfizer. Primary endpoints: Treatment-Emergent Adverse Events, Hopkins Verbal Learning Test-Revised Total Score at Week 17 and 4 more. Started Jun 2008; status: completed.
02
Drugs
tanezumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00669409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669409.